Office of Licensing & Ventures

Home


 OLV Overview

The Office of Licensing & Ventures (OLV) is responsible for patents, technology licenses and new venture development for Duke University and Medical Center.  Through direct, daily interaction with faculty, small and large businesses, and venture investors, we build strong relationships and strong agreements to translate academic discoveries into commercial products that benefit society, impact public health, and improve the quality of life. 

Latest News

Celsion Announces Issuance of U.S. Patent Covering ThermoDox(R) Technologies
April 13, 2011
New Patent Extends U.S. Intellectual Property Protection of ThermoDox(R) and Other Temperature-Sensitive Liposomal Formulations to 2021

Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer
November 11, 2010

Cellona Therapeutics, Inc. Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant for CT-10 Novel Targeted Cancer Compound
November 3, 2010

Cellona Therapeutics, Inc. and Duke Announce Exclusive Licensing Agreement and Collaboration to Develop Novel Cancer Drugs
September 14, 2010

Trevena Secures $35 Million in Series B Funding
July 14, 2010

Regado Biosciences, Inc. continues to expand its patent portfolio by announcing issuance of a new patent for its product candidates, the REG1 AND REG2 Anticoagulation Systems
June 22, 2010

Argos Therapeutics Presents Positive Phase 2 Data for Arcelis™ Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
June 8, 2010
-Interim Data in Combination with Sunitinib Demonstrate Positive Clinical Activity-

GrassRoots selected to participate in NCBC Industrial Fellowship Program
April 22, 2010

Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand
April 14, 2010

Bioptigen, Inc. Receives 2008 Frost & Sullivan North America
March 10, 2010

PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals
January 7, 2010

REGADO BIOSCIENCES, INC. COMPLETES $40 MILLION SERIES D FINANCING
December 17, 2009

Trevena Awarded $7.65 Million NIH Grant
November 3, 2009

Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
October 22, 2009
Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue

Centice Corporation closes on $6.1 million Series C financing
October 21, 2009
Funds to support commercialization of innovative PASS Rx® system

See all news